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Background: MicroRNA-21 has been proved to be associated with glioma proliferation and invasion; thus, we
sought to clarify the clinical value of miR-21 expression in glioma tissues with WHO grade I to IV.
Methods: One hundred and fifty-two pairs of human gliomas and non-neoplastic brain tissues were evaluated
using real-time PCR. The association of miR-21 expression with clinicopathological factors or the prognosis of glioma
patients was also analyzed. In this study, survival analysis was performed using the Kaplan-Meier method and Cox’s
proportional hazards model.
Results: MiR-21 was more greatly expressed in glioma tissues compared to the corresponding non-neoplastic brain
tissues (P < 0.001). This observed high miR-21 expression was significantly associated with high pathological grades
and the Karnofsky performance score of glioma patients. In addition, overall patient survival for those with low
miR-21 expression was significantly longer than those patients with high miR-21 expression (P < 0.001). Moreover,
multivariate Cox regression analysis indicated that miR-21 might be an independent prognostic marker for glioma
patient survival.
Conclusions: Our data show that miR-21 may be a candidate independent marker for gliomas, especially those with
high pathological grades, and this could also be a potential therapeutic target for molecular glioma therapy.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1445749171109834.
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Glioma, the most common primary malignant brain
tumor arising from the brain orspinal cord tissue, has a
tendency to invade the surrounding brain tissue. Gli-
omas represent approximately one-third of all intrinsic
neoplasms of the central nervous system in both adults
and children. The World Health Organization (WHO)
classification divides gliomas into grades I through IV,
and these values correspond to increasing levels of
malignancy, including well-differentiated low grade,
astrocytomas and glioblastoma multiforme [1]. Glioma
has a poor prognosis due to the characteristic progressive* Correspondence: biozhangj@hotmail.com; zhiguofmmu@163.com
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stated.overgrowth and diffuse invasion. Although the WHO clas-
sification can serve as a criterion to predict the patient clin-
ical outcomes, several recent studies have indicated that
this criteria alone may not be sufficient to estimate patient
prognosis [2,3]. Therefore, investigating molecular mecha-
nisms of gliomas may produce better prognostic markers
to anticipate patient survival.
MicroRNAs (miRNAs) are a class of small, evolution-
arily conserved, short non-coding endogenous RNA
molecules that regulate gene expression at the post-
transcriptional level [4]. Primary transcripts of miRNAs
(pri-miRNA) are generated by RNA polymerase II and
then they are sequentially processed by RNase III enzymes,
Drosha and Dicer, to first produce pre-miRNAs and finally
mature miRNAs. MiRNAs act by base-pairing with their
target mRNAs according to the degree of complementar-
ities with their target 3′ untranslated regions (UTRs) lead-
ing to their translational regulation and/or direct cleavage. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 The clinicopathological features and the









No. of cases 31 30 32 59
Mean age (Year) 44.1 45.9 42.9 46.5
Gender
Male 18 14 17 29
Female 13 16 15 30
KPS
≥70 29 20 10 3
<70 2 10 22 56
Surgery
Total resection 31 30 22 32
Partial resection 0 0 10 27
Adjuvant treatment
Radiotherapy 0 0 23 29
Chemotherapy 0 2 4 1
Radiotherapy + chemotherapy 0 0 4 29
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physiologic roles in cell proliferation and differentiation,
epithelial-mesenchymal transition, apoptosis and metabol-
ism [7,8]. In addition, studies suggest that miRNAs also
play important roles in tumorigenesis and tumor progres-
sion, acting as oncogenes or tumor suppressors depending
on their target genes. Finally, some miRNAs may be
markers for cancer diagnosis and prognosis [9,10].
In the present study, we focus on miR-21, which has been
demonstrated to act as either an oncogenic miRNA or an
anti-oncomiR (miRNA that negatively regulates oncogenes)
in various human malignancies including glioma [11-15].
However, to our knowledge, no correlation between miR-
21 and patient prognosis has not been addressed in glioma
at this time. To investigate this problem, miR-21 expression
in human gliomas and nonneoplastic brain tissues was
measured using real-time quantitative RT-PCR assay. The
association of miR-21 with clinicopathological factors or
glioma patient prognosis was also statistically analyzed.
Methods and materials
Patients and tissue samples
This study was approved by the Research Ethics Committee
of Tangdu Hospital of Fourth Military Medical University,
P. R. China. Written informed consent for the following
pathological analysis or experiments was obtained from all
of the patients before his/her surgery. All specimens were
handled and made anonymous according to the ethical and
legal standards.
One hundred and fifty-two pairs of glioma tissues includ-
ing adjacent non-neoplastic brain tissues were selected, and
the pathological information was retrieved from the ar-
chives of the Pathology Department of Tangdu Hospital,
Fourth Military Medical University, P. R. China, from 2000
and 2009. None of the patients had received chemotherapy
or radiotherapy prior to surgery. All the samples were
resected from primary surgery, and the tumor tissues and
the adjacent non-neoplastic brain tissues were divided by
tissue laser microdissection [16]. The specimens were snap-
frozen in liquid nitrogen and stored at -80°C for real-time
PCR assay. The clinicopathological features and the treat-
ment strategies of all the patients were indicated in Table 1.
Isolation of total RNA and real-time PCR analysis
MiR-21 expression in glioma and adjacent nonneoplastic
brain tissues was measured by real-time quantitative RT-
PCR. Total RNA was isolated from frozen samples using
Trizol reagent (Invitrogen, CA, U.S.A.) according to the
manufacturer’s protocol. The TaqMan microRNA assay
and TaqMan universal PCR master mix were used to de-
tect the expression of miRNA-21, and the U6 gene was
used as an internal control to normalize variances. Rela-
tive quantification of target miRNA expression was evalu-
ated using the comparative cycle threshold (CT) method.Each sample was examined in triplicate and the raw data
were presented as the relative quantity of target miRNA,
normalized with respect to U6.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0 for
Windows (SPSS Inc, IL, USA). The associations between
miR-21 expression and clinical characteristics were evalu-
ated by Mann-Whitney U test. Survival curves were esti-
mated by the Kaplan-Meier method, and data were
analyzed with the log-rank test. Cox proportional hazards
analysis was performed to calculate the hazard ratio
(HR) and the 95% confidence interval (CI) to evaluate
the association between miR-21 expression and sur-
vival. In addition, a multivariate Cox regression was
performed to adjust for other covariates. A value of P < 0.05
was considered statistically significant.
Results
Characteristics of patients
The characteristics of the 152 glioma patients involved
in the study cohort are shown in Table 1. Of the 152 gli-
oma patients, 74 were female (78 were male). The mean
patient age was 45.1 years (range: 5-80 years-of-age).
According to the WHO classification, 31, 30, 32, and 59
of the 152 glioma patients were classified as grade I, II,
III, and IV, respectively. The Karnofsky performance
score (KPS) to assess the well-being of 62 glioma pa-
tients was higher than 70 (able to care for self but un-
able to do active work), and the KPS of 90 patients was
lower than 70.
Table 2 Association of miR-21 expression level in glioma
tissues with gender, age, Karnofsky performance score






Low (n, %) High (n,%)
WHO Grade <0.001
I 31 31 (100%) 0 (0%)
II 30 30 (100%) 0 (0%)
III 32 18 (56.3%) 14 (43.7%)
IV 59 3 (5%) 56 (95%)
Gender 0.34
Male 78 45 (57.7%) 33 (42.3%)
Female 74 37 (50%) 37 (50%)
Age 0.23
<50 91 49 (53.8%) 42 (46.2%)
≥50 61 33 (54.1%) 28 (45.9%)
KPS <0.001
≥70 62 57 (91.9%) 5 (8.1%)
<70 90 25 (27.8%) 65 (72.2%)
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MiR-21 expression was detected in 152 pairs of glioma
and adjacent non-neoplastic brain tissues. Normalized to
the U6 gene, the relative miR-21 expression in glioma
samples was 20.99 ± 13.04 (mean ± SD), whereas the
relative miR-21 expression detected in adjacent non-
neoplastic normal tissues was 0.73 ± 0.05 (Figure 1A).
We also observed that miR-21 expression in high-grade
(III-IV) gliomas was higher than that observed in low-
grade (I-II) gliomas (P < 0.001) (Figure 1B) and this in-
crease was statistically significant.
Association between miR-21 expression and clinicopatho-
logical characteristics of gliomas
The correlation of miR-21 expression with different clin-
icopathological parameters in gliomas was illustrated in
Table 2. A close correlation was observed between miR-
21 expression and the WHO glioma pathological grade
(P < 0.001). Based on these data, the median miR-21 ex-
pression in all 152 glioma tissues was 20.99, thus we
classified all glioma samples into 2 groups: low expres-
sion (mean expression value 3.25, n = 61), and high ex-
pression groups (mean expression value 32.87, n = 91). A
significant relationship was also observed between miR-
21 expression and the KPS (P < 0.001). However, there
was no significant association between miR-21 expres-
sion and gender or age at diagnosis (Table 2).
Relationship of miR-21 expression with overall glioma
patient survival
To investigate the relationship between miR-21 expression
and clinical outcomes, we reviewed the clinical informa-
tion for all 152 glioma patients. During the follow-up
period, 36 glioma patients (23.68%) were still alive, but
116 patients (76.32%) died (85 from high miR-21 ex-
pression group, and 31 from low miR-21 expression group).
Kaplan-Meier survival curves suggested that gliomaFigure 1 The expression levels of miR-21 in 152 pairs of glioma and a
analysis. (A) Expression levels of miR-21 in glioma and non-neoplastic bra
tissues with pathological grades I to IV and homologous non-neoplastic brpatients with low miR-21 expression had a significantly
longer survival time than those with high miR-21 ex-
pression (P < 0.001; Figure 2). The survival rate of high
miR-21 expression was lower than the survival of other
patients, as determined by the log-rank test (p < 0.001).
The Cox proportional hazards model was adjusted for
several clinical parameters, and these data are shown in
Table 3. The Cox proportional hazards model indicated
that KPS and WHO grades were associated with overall
mortality, but that age, gender, the extent of resection
and type of adjuvant treatment were not. Multivariate
analysis also showed that high miR-21 expression was a
significant and independent indicator of poor prognosis
for patients with glioma.djacent non-neoplatic brain tissues detected by Real-Time PCR
in tissues respectively. (B) Expression levels of miR-21 in 152 glioma
ain tissues.
Table 3 Cox multivariate analysis
Parameter Risk 95% confidence interval P
Age 1.01 0.996-1.018 0.22
Gender 1.12 0.873-2.214 0.56
WHO grade 8.17 1.529-5.158 <0.001
KPS 0.29 0.204-1.131 <0.001
MiR-21 expression level 3.17 2.39-4.179 <0.001
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Glioma is one of the most common malignant tumors
with a low survival rate, especially in the face of high
WHO tumor grades (III, IV). Accurately predicting post-
operative outcomes in glioma patients and choosing the
correct adjuvant therapy is a present and persistent prob-
lem. At this time, traditional pathologic variables are used
to make such predictions. Currently, WHO glioma grades
are the gold standard for determining glioma patient prog-
nosis, but this information is less useful for individual pa-
tients and often fails to discriminate the biological nature
of a large number of gliomas. Therefore patients at the
same disease stage often have significant discrepancies in
survival times. Until now, there are several studies showed
that single molecule could be the relapse and prognosis
indicator [17,18]. Thus, discovering more molecular
markers associated with the relapse and prognosis of
glioma is essential.
To date, studies have shown that miRNA expression is
correlated with clinical and biological features of tumors,
including tissue type, differentiation and aggressiveness,
which can be a potential biomarker for therapy and
prognosis [10,12-14]. MiR-21 is one of the first discov-
ered miRNAs that is known to be widespread in human
tissues. Up-regulation of miR-21 has been observed in
numerous human cancers [13,15]. Several publications
confirm that miR-21 can promote cell proliferation and
invasion and that it inhibits cell apoptosis [19-21]. Inhib-
ition of miR-21 could upregulate the expression of a
miRNA-target tumor suppressor gene such as protein
tyrosine phosphatase (PTEN) and B cell translocation
gene 2 (BTG2), and thereby decreases tumor progression
[22-24]. However, to date there has been no research on
the prognostic role of miR-21 in glioma. New molecularFigure 2 Kaplan-Meier survival curves for 152 glioma patients with h
of 152 glioma patients with high or low miR-21 expression; (B) The 5-year
and II) in high or low miR-21 expression group. (C) The 5-year overall survi
high or low miR-21 expression group.prognostic factors for glioma may contribute to a better
assessment of survival probability and the tailoring of
treatments for individual patients.
We investigated miR-21 expression in glioma and deter-
mined if this marker could predict disease relapse and pa-
tient outcomes. We observed that increased miR-21
expression was evident in human glioma tissues compared
with non-neoplastic brain tissues. High miR-21 expression
in glioma tissues was significantly correlated with aggres-
sive clinicopathological features as well. Kaplan-Meier
analysis revealed that glioma patients with high miR-21
expression had poorer overall survival. Moreover, multi-
variate analysis revealed that high miR-21 expression was
a marker of worse patient outcomes which was independ-
ent of known clinical prognostic indicators such as KPS
and WHO grades. Gliomas with grade I have different
genetic abnormality compared with other grade gliomas.
In this study, we divided all the gliomas into two groups:
low grade glioma (WHO grade I and II) and high grade
glioma (WHO III and IV) and performed multivariate
analysis. The result also indicated that miR-21 could be
the marker of poor outcomes in these two groups (Rela-
tive Risk is 4.947, P value < 0.001, 95% confidence interval
is 3.12-7.843). All these data indicate that increased ex-
pression of miR-21 is correlated with poor glioma patientigh or low expression of miR-21. (A) The 5-year overall survival rate
overall survival rate of glioma patients with lower grade (WHO Grades I
val rate of glioma patients with high grade (WHO Grades III and IV) in
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tial biomarker for overall survival prediction in this patient
population.
Conclusions
Our results revealed that miRNA-21 was overexpressed
in glioma tumors and that high expression level of
miRNA-21 was strongly associated with poor prognosis,
but further prospective studies are needed to determine
the actual clinical relevance of this observation. Our data
suggest that miR-21 may be an appropriate prognostic
marker for evaluating advanced tumors with high patho-
logical grades and that this marker may assist with the
appropriate choice of adjuvant chemotherapy as well as
serve as a potential therapeutic target in molecular ther-
apy for glioma.
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